2017 International Congress

June 4-8, 2017. Vancouver, BC.

View by Title View Sessions

View by Date

Tuesday, June 6, 2017

1:45pm-3:15pm: Infusion Rate Dependent Acute Neuropathic Pain with Duopa™ in a Patient with Parkinson’s disease and Pre-Existing Neuropathy

A. Shukla, R. Govindarajan, I. Asher (Columbia, MO, USA)

Therapy in Movement Disorders · Exhibit Hall C

1:45pm-3:15pm: Inhaling xenon ameliorates L-DOPA-induced dyskinesia in Parkinson disease through normalizing maladaptive corticostriatal plasticity

E. Bezard, J. Bauffreton, Q. Li, G. Porras, W.K. Ko, E. Pioli, M. Cazalon, S. Morin, G. Farjot, J. Pype, B. Bessiere (Bordeaux, France)

Therapy in Movement Disorders · Exhibit Hall C

1:45pm-3:15pm: Inhibiting sphingosine-1-phosphate lyase as a possible therapy in Huntington’s disease

E. Furr Stimming, J.F. Manchon, A. Tsvetkov (Houston, TX, USA)

Huntington's Disease · Exhibit Hall C

1:45pm-3:15pm: Inhibition of long term memory and induction of biochemical deficits in rats following protofibrillar Aβ 1-42 injection

B. Nehru, S. Sharma (Chandigarh, India)

Pathophysiology (Other Movement Disorders) · Exhibit Hall C

1:45pm-3:15pm: Inhibition of mitochondrial complex I synthesis by chloramphenicol mitigates dopaminergic neuronal cell loss in PQ-induced parkinsonism

S.J. Kim, J. Han, Y. Jang, J. Kim, M.J. Lee, I. Ryu, X. Ju, M.J. Ryu, W. Chung, J.Y. Heo (Daejeon, Republic of Korea)

Parkinson's Disease: Pathophysiology · Exhibit Hall C

1:45pm-3:15pm: Instrumental Measurement of Stepping in Place – Detection of Asymmetry and Freezing of Gait

K. Otte, T. Vater, T. Ellermeyer, L. Rasche, G. Wenzel, B. Kayser, S. Mansow-Model, A. Kühn, F. Paul, A. Brandt, A. Lipp, T. Schmitz-Hübsch (Berlin, Germany)

Technology · Exhibit Hall C

1:45pm-3:15pm: Insulin Resistance In Non-Diabetic People With Parkinson’s Disease

M. Tagliati, E. Tan, J. Eskenazi, C. Basile, E. Hogg (Los Angeles, CA, USA)

Parkinson's Disease: Pathophysiology · Exhibit Hall C

1:45pm-3:15pm: Interaction between PLK2 ( Polo-like kinase-2) and alpha-synuclein in the non-human primate MPTP model of Parkinson disease

R. Valenti-Azcarate, I. Martinez-Valbuena, M.-M. Carmona-Abellan, I. Marcilla-Garcia, G. Marti-Andres, M.R. Luquin-Piudo (Pamplona, Spain)

Parkinson's Disease: Pathophysiology · Exhibit Hall C

1:45pm-3:15pm: Interaction of dietary protein with levodopa in Parkinson disease.

B. Sharma, A. Rassmann, T. Virmani (Little Rock, AR, USA)

Therapy in Movement Disorders · Exhibit Hall C

1:45pm-3:15pm: Intracerebroventricular administration of dopamine: A new therapeutic concept for Parkinson’s disease?

C. LALOUX, F. GOUEL, C. LACHAUD, K. Timmerman, A. Jonneaux, C. Moreau, R. BORDET, J.-c. DEVEDJIAN, D. DEVOS (LILLE, France)

Therapy in Movement Disorders · Exhibit Hall C